TNF and inflammatory bowel disease: Below are discussed factors that the panel believe may have limited the use of biosimilar anti-TNF-α medicines in IBD to date, with strategic suggestions to mitigate these potential ‘barriers’ and support accelerated use of anti-TNF-α therapy (summarized in Table 3).